Identification

Name
Sulpiride
Accession Number
DB00391  (APRD00032)
Type
Small Molecule
Groups
Approved, Investigational
Description

A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)

Structure
Thumb
Synonyms
  • (+-)-Sulpiride
  • 5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide
  • Levosulpirida
  • Levosulpiride
  • Levosulpiridum
  • N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide
  • N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-O-anisamide
  • Sulpirid
  • Sulpirida
  • Sulpiridum
  • Sulpyrid
International/Other Brands
Bosnyl / Dogmatil / Dogmatyl / Dolmatil / Eglonyl / Espiride / Meresa / Modal
Categories
UNII
7MNE9M8287
CAS number
15676-16-1
Weight
Average: 341.426
Monoisotopic: 341.140926929
Chemical Formula
C15H23N3O4S
InChI Key
BGRJTUBHPOOWDU-UHFFFAOYSA-N
InChI
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
IUPAC Name
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
SMILES
CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O

Pharmacology

Indication

Sulpiride is indicated for the treatment of schizophrenia.

Structured Indications
Not Available
Pharmacodynamics

Sulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.

Mechanism of action

In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, Sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 3
inhibitor
Human
Absorption

Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

6 to 8 hours

Clearance
Not Available
Toxicity

Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineSulpiride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3-Hydroxyhippuric acidThe risk or severity of adverse effects can be increased when 3-Hydroxyhippuric acid is combined with Sulpiride.Experimental
3,4-MethylenedioxyamphetamineSulpiride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineSulpiride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sulpiride is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sulpiride.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sulpiride.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Sulpiride.Approved
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Acetyldigoxin.Experimental
AclidiniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Aclidinium.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alaproclate.Experimental
AlcuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Sulpiride.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Allopregnanolone.Investigational
AlmasilateThe serum concentration of Sulpiride can be decreased when it is combined with Almasilate.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sulpiride.Approved, Investigational
AloglutamolThe serum concentration of Sulpiride can be decreased when it is combined with Aloglutamol.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sulpiride.Approved, Illicit, Investigational
AluminiumThe serum concentration of Sulpiride can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Sulpiride can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Sulpiride can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum hydroxide.Approved
Aminohippuric acidThe risk or severity of adverse effects can be increased when Aminohippuric acid is combined with Sulpiride.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Sulpiride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sulpiride.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Sulpiride.Experimental
AmphetamineSulpiride may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Anisotropine MethylbromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Anisotropine Methylbromide.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulpiride.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Sulpiride.Approved
AtracuriumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atracurium.Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atracurium besylate.Approved
AtropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Sulpiride.Investigational, Vet Approved
AzelastineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Sulpiride is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital.Illicit
BenactyzineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benactyzine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sulpiride.Approved
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Sulpiride.Investigational
BenzatropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benzatropine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzocaine.Approved
BenzphetamineSulpiride may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzyl alcohol.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Bezafibrate is combined with Sulpiride.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Sulpiride.Investigational
BiperidenThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Biperiden.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Sulpiride can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Sulpiride can be decreased when it is combined with Bismuth subnitrate.Experimental
BornaprineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Bornaprine.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Sulpiride.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sulpiride.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.Approved, Investigational
BromoprideThe risk or severity of adverse effects can be increased when Bromopride is combined with Sulpiride.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Sulpiride.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sulpiride.Approved, Investigational
BuprenorphineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sulpiride.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sulpiride.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butamben.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Sulpiride.Experimental
ButethalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sulpiride.Approved, Illicit, Vet Approved
ButylscopolamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Butylscopolamine.Approved, Vet Approved
CabergolineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cabergoline.Approved
Calcium CarbonateThe serum concentration of Sulpiride can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Sulpiride can be decreased when it is combined with Calcium silicate.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Sulpiride is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sulpiride.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Sulpiride.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sulpiride.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorphenamine.Approved
ChlorphenoxamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Chlorphenoxamine.Withdrawn
ChlorphentermineSulpiride may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Sulpiride.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sulpiride.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sulpiride.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sulpiride.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cinchocaine.Approved, Vet Approved
CisaprideThe risk or severity of adverse effects can be increased when Cisapride is combined with Sulpiride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Sulpiride.Approved
ClemastineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Sulpiride is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Sulpiride.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sulpiride.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Sulpiride.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sulpiride.Approved
CocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sulpiride.Approved, Illicit
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Sulpiride.Approved
CyclizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sulpiride.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Sulpiride.Experimental
CyclopentolateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cyclopentolate.Approved
CymarinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cymarin.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sulpiride.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dapoxetine.Investigational
DarifenacinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Darifenacin.Approved, Investigational
declopramideThe risk or severity of adverse effects can be increased when declopramide is combined with Sulpiride.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sulpiride.Approved
DesipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desipramine.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deslanoside.Approved
DesloratadineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sulpiride.Approved
DetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexbrompheniramine.Approved
DexetimideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dexetimide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineSulpiride may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sulpiride.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Sulpiride.Approved, Illicit, Vet Approved
DicyclomineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dicyclomine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diethyl ether.Experimental
DiethylpropionSulpiride may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Difenoxin.Approved, Illicit
DigitoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sulpiride.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulpiride.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sulpiride.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sulpiride.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Sulpiride.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Sulpiride is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sulpiride.Approved
DyclonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Sulpiride.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Sulpiride is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sulpiride.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Eltanolone.Investigational
EmeproniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Emepronium.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sulpiride.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulpiride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sulpiride.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Sulpiride.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Sulpiride.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sulpiride.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sulpiride.Approved
EtanautineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Etanautine.Experimental
EthanolSulpiride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride.Approved, Illicit, Withdrawn
EthopropazineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ethopropazine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Etybenzatropine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sulpiride.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sulpiride.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Fesoterodine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Sulpiride.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sulpiride.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sulpiride.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sulpiride.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sulpiride.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sulpiride.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sulpiride.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Sulpiride.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sulpiride.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gabapentin Enacarbil.Approved
GallamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Gallamine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Sulpiride.Approved, Illicit, Investigational
GepefrineSulpiride may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gepirone.Investigational
GitoformateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gitoformate.Experimental
GlutethimideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sulpiride.Approved
HalothaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hexobarbital.Approved
HomatropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Homatropine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sulpiride.Approved, Vet Approved
HydrocodoneSulpiride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sulpiride.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride.Approved, Illicit
HydrotalciteThe serum concentration of Sulpiride can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
HydroxyamphetamineSulpiride may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
HyoscyamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hyoscyamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sulpiride.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Sulpiride.Approved
ImipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.Approved
IndiplonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Sulpiride.Withdrawn
Iofetamine I-123Sulpiride may decrease the stimulatory activities of Iofetamine I-123.Approved
Ipratropium bromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ipratropium bromide.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sulpiride.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Sulpiride.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sulpiride.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lamotrigine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lanatoside C.Experimental
LevetiracetamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Sulpiride.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sulpiride.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sulpiride.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Sulpiride.Approved, Investigational
LisdexamfetamineSulpiride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Sulpiride.Approved
LofentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sulpiride.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sulpiride.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sulpiride.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sulpiride.Approved
MagaldrateThe serum concentration of Sulpiride can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Maprotiline.Approved
MazaticolThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Mazaticol.Experimental
MebicarThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mebicar.Experimental
MecamylamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Sulpiride is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Sulpiride.Approved, Investigational
MephedroneSulpiride may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineSulpiride may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Meptazinol.Experimental
MequitazineSulpiride may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sulpiride.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineSulpiride may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethanthelineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Methantheline.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methaqualone.Illicit, Withdrawn
MethenamineThe risk or severity of adverse effects can be increased when Methenamine is combined with Sulpiride.Approved, Vet Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sulpiride.Approved
MethotrimeprazineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineSulpiride may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethscopolamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Methscopolamine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Methylscopolamine bromide.Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Metildigoxin.Experimental
MetixeneThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Metixene.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.Approved
MetyrosineSulpiride may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sulpiride.Approved, Illicit
MidomafetamineSulpiride may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Sulpiride.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
MirtazapineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDASulpiride may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sulpiride.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Sulpiride.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Sulpiride.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sulpiride.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Sulpiride.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sulpiride.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sulpiride.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sulpiride.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sulpiride.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Sulpiride.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sulpiride.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oleandrin.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sulpiride.Approved
OpiumThe risk or severity of adverse effects can be increased when Sulpiride is combined with Opium.Approved, Illicit
OrphenadrineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Sulpiride.Investigational
OtiloniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ouabain.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sulpiride.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxethazaine.Approved, Investigational
OxitropiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxitropium.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxybuprocaine.Approved
OxybutyninThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sulpiride.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sulpiride.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Sulpiride.Experimental
OxyphenoniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxyphenonium.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sulpiride.Approved
PancuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pancuronium.Approved
ParaldehydeSulpiride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sulpiride.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Sulpiride.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sulpiride.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sulpiride.Approved, Vet Approved
PentoliniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Sulpiride.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Sulpiride.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sulpiride.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sulpiride.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sulpiride.Approved
PhenglutarimideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Phenglutarimide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sulpiride.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenoxyethanol.Approved
PhentermineSulpiride may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sulpiride.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sulpiride.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sulpiride.Approved, Investigational
PirenzepineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pirenzepine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Sulpiride.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Sulpiride.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pomalidomide.Approved
PramipexoleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sulpiride.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Sulpiride.Approved
ProcaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sulpiride.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sulpiride.Approved, Vet Approved
ProcyclidineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Procyclidine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sulpiride.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propanidid.Experimental
PropanthelineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Propantheline.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Sulpiride.Approved
PropiverineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Sulpiride.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propoxycaine.Approved
ProscillaridinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proscillaridin.Experimental
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Sulpiride.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Sulpiride is combined with PSD502.Investigational
PseudoephedrineSulpiride may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Sulpiride.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sulpiride.Approved
QuinagolideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Quinagolide.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Sulpiride.Approved
QuinidineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Quinidine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Sulpiride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sulpiride.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sulpiride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sulpiride.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Sulpiride.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sulpiride.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Sulpiride.Investigational
RitobegronSulpiride may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sulpiride.Approved
RomifidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Romifidine.Vet Approved
RopiniroleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sulpiride.Approved
RotigotineSulpiride may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sulpiride.Approved
ScopolamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sulpiride.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sulpiride.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Sulpiride.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Sulpiride.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sulpiride.Approved, Vet Approved
Sodium bicarbonateThe serum concentration of Sulpiride can be decreased when it is combined with Sodium bicarbonate.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
SolifenacinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Solifenacin.Approved
StiripentolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Stiripentol.Approved
SucralfateThe serum concentration of Sulpiride can be decreased when it is combined with Sucralfate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Sulpiride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sulpiride.Approved, Investigational
SuvorexantSulpiride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sulpiride.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sulpiride.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sulpiride.Approved
TetracaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Sulpiride.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetrodotoxin.Investigational
ThalidomideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Sulpiride.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Sulpiride.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sulpiride.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sulpiride.Approved
TiagabineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Sulpiride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tilidine.Experimental
TiotropiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tolcapone.Approved, Withdrawn
TolterodineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sulpiride.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Sulpiride.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Sulpiride.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sulpiride.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Sulpiride.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sulpiride.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trihexyphenidyl.Approved
TrimethaphanThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triprolidine.Approved
TromethamineThe serum concentration of Sulpiride can be decreased when it is combined with Tromethamine.Approved
TropatepineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tropatepine.Experimental
TropicamideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tropicamide.Approved
TrospiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trospium.Approved
TubocurarineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tubocurarine.Approved
UmeclidiniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Umeclidinium.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sulpiride.Approved, Investigational
VecuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sulpiride.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Sulpiride.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Sulpiride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Sulpiride.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sulpiride.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sulpiride.Approved
ZoaleneThe risk or severity of adverse effects can be increased when Zoalene is combined with Sulpiride.Vet Approved
ZolazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sulpiride.Approved, Investigational
ZolpidemSulpiride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Sulpiride.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Sulpiride.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sulpiride.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14535
KEGG Drug
D01226
PubChem Compound
5355
PubChem Substance
46504855
ChemSpider
5162
BindingDB
11638
ChEBI
32168
ChEMBL
CHEMBL26
Therapeutic Targets Database
DAP000310
PharmGKB
PA164745485
IUPHAR
958
Guide to Pharmacology
GtP Drug Page
Wikipedia
Sulpiride
ATC Codes
N05AL07 — LevosulpirideN05AL01 — Sulpiride
MSDS
Download (57 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceIndigestion1
2, 3CompletedTreatmentAcute Agitation1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)178 dec °CPhysProp
water solubility2280 mg/LNot Available
logP0.57HOEGBERG,T ET AL. 1986
Caco2 permeability-6.16ADME Research, USCD
pKa9.12EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.537 mg/mLALOGPS
logP1.2ALOGPS
logP0.22ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)10.24ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity88.63 m3·mol-1ChemAxon
Polarizability36.18 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9444
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7319
P-glycoprotein inhibitor INon-inhibitor0.857
P-glycoprotein inhibitor IINon-inhibitor0.8994
Renal organic cation transporterNon-inhibitor0.7685
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.54
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9656
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9409
Ames testNon AMES toxic0.6229
CarcinogenicityNon-carcinogens0.7139
BiodegradationNot ready biodegradable0.8542
Rat acute toxicity1.8612 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8546
hERG inhibition (predictor II)Inhibitor0.549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0109000000-838e3fc396f400ef6f4b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-2901000000-15575a206ad43d931d6a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-3900000000-b83b6287d83301602f00
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a6r-8900000000-5a447dc363e7b3d43351
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9200000000-0a29790b32c5ae5e192a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-32eb95f9c75cc8d8ee85
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0009000000-b451c07c9adbe534b75c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ox-0049000000-eaadc21e5bafdd34a66e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-16b776d58e4e2dbc163e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-9fda88d7482dee887457
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0009000000-338379e29df68a5396b7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0209000000-d61c87359158078fa846
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-2931000000-6a28d0dd33433a572e50
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-4940000000-dcee56e4387108740566
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-8960000000-9f1a7605079446735287
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03e9-9620000000-c3bb475e828d5f8c88aa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-3972000000-4f53a77ce37004c9eac3

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Organosulfonamides / N-alkylpyrrolidines / Aminosulfonyl compounds / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds
show 5 more
Substituents
Benzenesulfonamide / Benzenesulfonyl group / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Organosulfonic acid amide / N-alkylpyrrolidine / Pyrrolidine
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, benzamides, N-alkylpyrrolidine (CHEBI:32168)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185]
  2. Jaber M, Tison F, Fournier MC, Bloch B: Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res Mol Brain Res. 1994 Apr;23(1-2):14-20. [PubMed:7518029]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Lipina TV, Vishnivetskaia GB: [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):482-7. [PubMed:19795811]
  2. Collo G, Zanetti S, Missale C, Spano P: Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008 Oct;28(7):1231-40. doi: 10.1111/j.1460-9568.2008.06423.x. [PubMed:18973551]
Details
3. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]
Details
4. Carbonic anhydrase 3
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA3
Uniprot ID
P07451
Uniprot Name
Carbonic anhydrase 3
Molecular Weight
29557.215 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Vacca C, Maione S, Tozzi A, Marmo E: Benzamides and cholinesterases. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):193-201. [PubMed:3823608]
  2. Dross K: [The relevance of anticholinesterase properties to toxicity and neuromuscular effects of sulpiride (author's transl)]. Arzneimittelforschung. 1977 Feb;27(2):404-6. [PubMed:577162]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:36